Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Biosimilars
70 Articles Available
0
3
Can't find what you're looking for? Try our
advanced search
.
Analytical Method Development
Harnessing Biologic Development Experience in Support of CDMO Clients: Rapid, Effective and Tailored Analytical Method Development
PAO-03-24-CL-09
Biotherapeutics
Leveraging the Tenacity of Biotherapeutics Development Experience to Build a Dynamic CDMO
PAO-10-23-CL-05
Interchangeable Biosimilars
The Opportunities and Challenges Posed by Biosimilar Interchangeability
PAO-03-23-NI-01
Life Science Industrials
Filling Industry Gaps and Driving Innovation with Life Science Industrials
PAO-11-21-CL-01
Phase 3 Biosimilar
Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra®
PR-M06-21-010
Clinical Trial Logistics
Innovative Strategies to Maintain Product Integrity in Biologic and Biosimilar Clinical Studies
PAO-03-21-CL-06
Biosimilars
Successful Biosimilar Development Requires an Outsourcing Partner with the Right Experience
PAO-03-21-CL-03
Parenterals
Trends Shaping the Dynamic Market for Parenterals
PAP-Q3-20-CL-018
The Future of Healthcare
How Is Polpharma Biologics Evolving its Business Model to Meet the Future of Healthcare?
PAP-Q3-20-RT2-007
The Future of Healthcare
How is Polpharma Biologics Innovating through the Integration of Advanced Cell Line Development Capabilities to Help Shape the Future of Healthcare?
PAP-Q2-20-RT2-004
Biosimilar
iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab Biosimilar
PR-M04-20-NI-014
BLA
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
PR-M03-20-NI-014
Biosimilars
FDA Statement on Low-Cost Biosimilar and Interchangeable Protein Products
PR-M12-19-NI-037
Biosimilars
Numerous Biosimilar Launches Coming Soon in United States
PAO-M12-19-NI-007
FDA Approval
Sandoz Receives FDA Approval for Oncology Supportive Care Biosimilar Ziextenzo™
PR-M11-19-NI-006
Biosimilars
Is the U.S. Biosimilars Market Poised for Takeoff?
PAP-Q3-19-CL-015
Biosimilar
Dr. Reddy's Laboratories Announces the Launch of Versavo® (bevacizumab biosimilar) in India
PR-M08-19-NI-063
Biosimilars
Celltrion and Nan Fung Group to establish Vcell Healthcare Limited to Develop and Commercialize Biosimilars in China
PR-M07-19-NI-058
Biosimilar
Prestige BioPharma Releases Positive Results from Phase I Study of HD204, Biosimilar Candidate to Bevacizumab
PR-M07-19-NI-020
FDA Approval
Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)
PR-M07-19-NI-015
Biosimilar Approval
Herceptin Biosimilar Approved in the U.S.
PAO-M06-19-NI-017
Biosimilar
Successful Results Reported for Another Rituximab Biosimilar
PAO-M05-19-NI-020
Biosimilars
Accelerating Biosimilar Development
PAP-Q1-2019-CL-014
Biosimilar
Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
PR-M01-19-NI-079
«
0
3
»
.svg)